News

Niclosamide was recently identified by Institut Pasteur Korea as a potent inhibitor of SARS-CoV-2, the virus causing COVID-191. For a number of years, UNION has worked with niclosamide

The acceptance of IND will allow Enzychem to assess EC-18 in a phase 2 clinical study in patients with ARDS due to Covid-19. The EC-18 is originally obtained

Started in May 2020, BLADE-CONQUER (ClinicalTrials.gov NCT04334460) is a double-blind, placebo-controlled clinical trial assessing the efficacy and safety of BLD-2660 on lung function and recovery time in hospitalized

Childhood ILD (chILD) includes more than 200 rare respiratory disorders that can affect infants, children and adolescents, making it difficult for them to breathe. In some cases, fibrosis

Both companies have not disclosed the financial terms of the deal. The research will include the application of GeneCentric’s advanced RNA-based molecular profiling platform to illustrate the potential

Today’s award of up to $1.525bn is for the manufacturing and delivery of 100 million doses of mRNA-1273 including incentive payments for timely delivery of the product. With

In the trial, treatment with Opdivo following neoadjuvant chemoradiation therapy (CRT) and complete surgical resection demonstrated a statistically significant improvement in the primary endpoint of DFS compared to

According to the company, SAB-185 is a fully-human, specifically targeted, and broadly neutralising polyclonal antibody therapeutic candidate. Besides potentially treating Covid-19 patients, the drug candidate can provide protective

The acquisition of KaNDy Therapeutics will allow Bayer to expand its drug development pipeline in women’s healthcare. The deal also allows KaNDy Therapeutics to secure potential milestone payments